TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome.

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

This post hoc sub-analysis of the TICO study goes along the same lines as the TWILIGHT study (which we recently discussed), given that age is the most common reason for considering that a patient is at high risk of bleeding. 

The analysis sought to find an age-dependent effect in patients who received 3 months of DAPT and then were randomized to ticagrelor monotherapy vs. completing 12 months of DAPT.

To answer this question, TICO included 3056 patients (mean age 61 years) and defined as primary endpoint a composite of major bleeding, death, infarction, stent thrombosis, stroke, or target-vessel revascularization.

The effect on bleeding reduction increased gradually with age, peaking at 64 years.


Read also: Post-PCI Ticagrelor Monotherapy in High-Risk Bleeding.


Considering 64 years as the cutoff point, the occurrence of the primary endpoint was significantly lower with ticagrelor monotherapy compared with patients who completed one year of DAPT (4.4% vs 9.0%; p = 0.002). In younger patients (n=1778), the difference between the two strategies was not significant.

Conclusion

There is an age-dependent effect that increases the benefit of ticagrelor monotherapy (after 3 months of DAPT) vs. completing a year of DAPT in patients admitted with acute coronary syndrome. Discontinuing aspirin at 3 months is superior in the elderly compared with younger patients, for whom the difference between strategies is not significant.

JAHA-121-022700

Original Title: Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. 

Reference: Byung Gyu Kim et al. J Am Heart Assoc. 2021 Dec 21;10(24):e022700. doi: 10.1161/JAHA.121.022700.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...